Chemed’s Q2 results exceeded Wall Street’s expectations, prompting a positive response from investors. Management attributed the performance primarily to strong patient volume growth and improved admission trends at VITAS, where hospital-based admissions and expansion in new Florida markets drove higher utilization. CEO Kevin McNamara highlighted that VITAS “continues to add ADC through accelerated admissions from non-preadmission locations while also maintaining a high level of hospital-based admissions.” At Roto-Rooter, commercial business manager programs contributed to revenue growth, although increased marketing spend due to a higher reliance on paid leads was a notable headwind.
Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).
Chemed (CHE) Q2 CY2026 Highlights:
- Revenue: $673.3 million vs analyst estimates of $665 million (8.8% year-on-year growth, 1.2% beat)
- Adjusted EPS: $6.06 vs analyst estimates of $5.60 (8.2% beat)
- Adjusted EBITDA: $121.8 million vs analyst estimates of $116.8 million (18.1% margin, 4.3% beat)
- Adjusted EPS guidance for the full year is $25.38 at the midpoint, beating analyst estimates by 4.2%
- Operating Margin: 13.2%, up from 11% in the same quarter last year
- Sales Volumes rose 6.1% year on year, in line with the same quarter last year
- Market Capitalization: $7.04 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Chemed’s Q2 Earnings Call
- Ben Hendrix (RBC Capital Markets) asked about the sustainability of VITAS’s growth and patient mix. CEO Joel Wherley replied that the growth is sustainable, citing improved KPI management and strong historical growth rates.
- Hendrix (RBC Capital Markets) inquired about Roto-Rooter’s paid versus free lead trends and margin impact. CFO Michael Witzeman explained that while paid leads now dominate, the situation is stable, and management is seeking alternative lead generation strategies.
- Brian Tanquilut (Jefferies) asked about VITAS margin drivers and long-term sustainability. Wherley emphasized that balancing hospital and community-based admissions expands margins, and Witzeman added that back office leverage supports future margin stability.
- Tanquilut (Jefferies) questioned Roto-Rooter’s willingness to pursue new service lines. CEO McNamara noted that while past expansions have been mixed, the company remains open to new opportunities that fit their model but is cautious based on historical results.
- Joanna Gajuk (Bank of America) probed on Roto-Rooter margin offsets amid rising marketing costs. McNamara and Witzeman said that higher conversion rates in ancillary services and improved collections help maintain margins despite higher expenses.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will be tracking (1) the ramp-up of patient admissions and census in VITAS’s new Florida counties, (2) stabilization or improvement in Roto-Rooter’s marketing efficiency and conversion rates for ancillary services, and (3) the pace and integration of new franchise acquisitions. Regulatory updates impacting hospice reimbursement and expansion opportunities in certificate-of-need states will also be important indicators.
Chemed currently trades at $540.77, up from $517.63 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
